Development and Validation of Nomograms to Predict Overall Survival and Cancer-Specific Survival in Patients With Pancreatic Adenosquamous Carcinoma.
cancer-specific survival
chemotherapy
nomogram
overall survival
pancreatic adenosquamous carcinoma
surgery
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2022
2022
Historique:
received:
08
12
2021
accepted:
31
01
2022
entrez:
25
3
2022
pubmed:
26
3
2022
medline:
26
3
2022
Statut:
epublish
Résumé
Pancreatic adenosquamous carcinoma (PASC) is a heterogeneous group of primary pancreatic cancers characterized by the coexistence of both glandular and squamous differentiation. The aim of this study was to develop nomograms to predict survival outcomes in patients with PASC. In this retrospective study, data on PASC, including clinicopathological characteristics, treatments, and survival outcomes, were collected from the SEER database between 2000 and 2018. The primary endpoints were overall survival (OS) and cancer-specific survival (CSS). The eligible patients were randomly divided into development cohort and validation cohort in a 7:3 ratio. The nomograms for prediction of OS and CSS were constructed by the development cohort using a LASSO-Cox regression model, respectively. Besides the model performance was internally and externally validated by examining the discrimination, calibration, and clinical utility. A total of 632 consecutive patients who had been diagnosed with PASC were identified and randomly divided into development (n = 444) and validation (n = 188) cohorts. In the development cohort, the estimated median OS was 7.0 months (95% CI: 6.19-7.82) and the median CSS was 7.0 months (95% CI: 6.15-7.85). In the validation cohort, the estimated median OS was 6.0 months (95% CI: 4.46-7.54) and the median CSS was 7.0 months (95% CI: 6.25-7.75). LASSO-penalized COX regression analysis identified 8 independent predictors in the OS prediction model and 9 independent risk factors in the CSS prediction model: age at diagnosis, gender, year of diagnosis, tumor location, grade, stage, size, lymph node metastasis, combined metastasis, surgery, radiation, and chemotherapy. The Harrell C index and time-dependent AUCs manifested satisfactory discriminative capabilities of the models. Calibration plots showed that both models were well calibrated. Furthermore, decision curves indicated good utility of the nomograms for decision-making. Nomogram-based models to evaluate personalized OS and CSS in patients with PASC were developed and well validated. These easy-to-use tools will be useful methods to calculate individualized estimate of survival, assist in risk stratification, and aid clinical decision-making.
Sections du résumé
Background
UNASSIGNED
Pancreatic adenosquamous carcinoma (PASC) is a heterogeneous group of primary pancreatic cancers characterized by the coexistence of both glandular and squamous differentiation. The aim of this study was to develop nomograms to predict survival outcomes in patients with PASC.
Methods
UNASSIGNED
In this retrospective study, data on PASC, including clinicopathological characteristics, treatments, and survival outcomes, were collected from the SEER database between 2000 and 2018. The primary endpoints were overall survival (OS) and cancer-specific survival (CSS). The eligible patients were randomly divided into development cohort and validation cohort in a 7:3 ratio. The nomograms for prediction of OS and CSS were constructed by the development cohort using a LASSO-Cox regression model, respectively. Besides the model performance was internally and externally validated by examining the discrimination, calibration, and clinical utility.
Results
UNASSIGNED
A total of 632 consecutive patients who had been diagnosed with PASC were identified and randomly divided into development (n = 444) and validation (n = 188) cohorts. In the development cohort, the estimated median OS was 7.0 months (95% CI: 6.19-7.82) and the median CSS was 7.0 months (95% CI: 6.15-7.85). In the validation cohort, the estimated median OS was 6.0 months (95% CI: 4.46-7.54) and the median CSS was 7.0 months (95% CI: 6.25-7.75). LASSO-penalized COX regression analysis identified 8 independent predictors in the OS prediction model and 9 independent risk factors in the CSS prediction model: age at diagnosis, gender, year of diagnosis, tumor location, grade, stage, size, lymph node metastasis, combined metastasis, surgery, radiation, and chemotherapy. The Harrell C index and time-dependent AUCs manifested satisfactory discriminative capabilities of the models. Calibration plots showed that both models were well calibrated. Furthermore, decision curves indicated good utility of the nomograms for decision-making.
Conclusion
UNASSIGNED
Nomogram-based models to evaluate personalized OS and CSS in patients with PASC were developed and well validated. These easy-to-use tools will be useful methods to calculate individualized estimate of survival, assist in risk stratification, and aid clinical decision-making.
Identifiants
pubmed: 35330710
doi: 10.3389/fonc.2022.831649
pmc: PMC8940199
doi:
Types de publication
Journal Article
Langues
eng
Pagination
831649Informations de copyright
Copyright © 2022 Yang, Shi and Zhang.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Lancet. 2016 Jul 2;388(10039):73-85
pubmed: 26830752
Korean J Intern Med. 2011 Sep;26(3):348-51
pubmed: 22016596
Biom J. 2010 Feb;52(1):50-69
pubmed: 20166132
Lancet. 2020 Jun 27;395(10242):2008-2020
pubmed: 32593337
BMC Med Res Methodol. 2017 Apr 7;17(1):53
pubmed: 28388943
Jpn J Clin Oncol. 2020 May 5;50(5):483-489
pubmed: 32083290
J Pathol. 2017 Nov;243(3):271-272
pubmed: 28816351
Theor Appl Genet. 2012 Aug;125(3):419-35
pubmed: 22622521
Diagn Cytopathol. 2011 Jul;39(7):536-9; quiz 539-40
pubmed: 20949450
J Natl Compr Canc Netw. 2019 May 1;17(5.5):603-605
pubmed: 31117041
J Surg Res. 2012 May 1;174(1):12-9
pubmed: 21816433
Histopathology. 2020 Jan;76(2):182-188
pubmed: 31433515
Mod Pathol. 2001 May;14(5):443-51
pubmed: 11353055
Drugs. 2020 May;80(7):647-669
pubmed: 32306207
Cancer Med. 2020 Mar;9(5):1703-1711
pubmed: 31945808
J Surg Oncol. 2018 Jul;118(1):21-30
pubmed: 29878370
Abdom Radiol (NY). 2019 Aug;44(8):2822-2834
pubmed: 31187197
CA Cancer J Clin. 2020 Sep;70(5):375-403
pubmed: 32683683
Lancet. 2017 Mar 11;389(10073):1011-1024
pubmed: 28129987
J Cell Physiol. 2018 Apr;233(4):3352-3374
pubmed: 28926090
J Gastrointest Surg. 2011 Jan;15(1):165-74
pubmed: 21082275
Histochem Cell Biol. 2020 Jul;154(1):97-105
pubmed: 32170368
Biostatistics. 2013 Sep;14(4):682-94
pubmed: 23632625
CA Cancer J Clin. 2019 Jan;69(1):7-34
pubmed: 30620402
Digestion. 2005;72(2-3):104-8
pubmed: 16172546
Stat Med. 1996 Feb 28;15(4):361-87
pubmed: 8668867
Nat Rev Dis Primers. 2016 Apr 21;2:16022
pubmed: 27158978
Pancreas. 2014 Mar;43(2):287-90
pubmed: 24518509
Pancreatology. 2014 May-Jun;14(3):221-6
pubmed: 24854619
Cochrane Database Syst Rev. 2018 Mar 20;3:CD011044
pubmed: 29557103
Eur J Cancer. 1971 Aug;7(4):307-15
pubmed: 4328281
Surgery. 2021 May;169(5):1102-1109
pubmed: 33376004
World J Gastrointest Oncol. 2015 Sep 15;7(9):132-40
pubmed: 26380056
Int J Epidemiol. 2018 Apr 1;47(2):427-439
pubmed: 29149259
Eur Urol. 2018 Dec;74(6):796-804
pubmed: 30241973
Pancreas. 2019 Jul;48(6):817-822
pubmed: 31210663
Int J Mol Sci. 2017 Jun 22;18(7):
pubmed: 28640192
Future Oncol. 2016 Aug;12(16):1929-46
pubmed: 27246628
J Pathol. 2017 Oct;243(2):155-159
pubmed: 28722109
Nat Rev Gastroenterol Hepatol. 2018 Jun;15(6):333-348
pubmed: 29717230
World J Gastroenterol. 2018 Nov 21;24(43):4846-4861
pubmed: 30487695
Radiographics. 2020 Sep-Oct;40(5):1219-1239
pubmed: 32678699
Eur J Surg Oncol. 2021 Jul;47(7):1734-1741
pubmed: 33622577
Int J Mol Sci. 2017 Jul 26;18(8):
pubmed: 28933761
Prev Vet Med. 2018 Jan 1;149:107-114
pubmed: 29290291
J Am Coll Surg. 2008 Sep;207(3):368-70
pubmed: 18722942
Cancer. 2003 Dec 25;99(6):372-8
pubmed: 14681946